Skip to main content
. 2013 Jul 19;8(7):e69302. doi: 10.1371/journal.pone.0069302

Figure 2. ONO-1301 enhanced SDF-1 secretion and BMC migration via SDF-1/CXCR4 signaling after MI.

Figure 2

A–C) The SDF-1, HGF, and VEGF expression at the border zone of the infarcted area was measured by quantitative RT-PCR. The expression levels of these cytokines were higher in the ONO-1301-treated (O) group compared to the vehicle (V) group. (O group, n = 7; V group, n = 7–8; *P<0.05 vs. V group). The expression relative to GAPDH is shown. D) BMC migration to ONO-1301-treated infarcted myocardium was evaluated using IVIS. Representative picture of IVIS at day 3. Left: 100 mg/Kg, Center: 0 mg/Kg, Right: 100 mg/Kg+AMD3100 (AMD). E) The number of accumulated BMCs was greater in the 100 mg/kg ONO-1301-treated infarcted heart compared to the 0 and 10 mg/kg ONO-1301-treated infarcted heart. When BMCs treated with AMD were injected, the BMC accumulation decreased in the 100 mg/Kg ONO-1301-treated infarcted heart compared with the untreated-BMC-injected heart (0 mg/Kg, n = 4; 10 mg/Kg, n = 8; 100 mg/Kg, n = 5; 100 mg/Kg+AMD3100, n = 4; *P<0.05 vs. 0 mg/Kg, †P<0.05 vs. 10 mg/Kg, ‡P<0.05 vs. 100 mg/Kg).